Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of DWJ1543 with Concomitant DWC202307 in Healthy Volunteers
NCT05954338Phase 1Unknown
- Sponsor
- Daewoong Pharmaceutical
- Start
- Aug 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of enavogliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum plasma concentration at steady-state and Area under the curve from the time of dosing to the last measurable concentration. Status: unknown.
02
Drugs
enavogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05954338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05954338.